1099-1557/asset/PDS_left.gif?v=1&s=f962ae698249deba4dc56217f1bb95eac528fe4d)
1099-1557/asset/PDS_right.gif?v=1&s=44103455c6e4e28135198609bb6a426efee9a51c)
Original Report
You have free access to this content
A protocol for active surveillance of acute myocardial infarction in association with the use of a new antidiabetic pharmaceutical agent
Article first published online: 19 JAN 2012
DOI: 10.1002/pds.2337
Copyright © 2012 John Wiley & Sons, Ltd.
Issue
Pharmacoepidemiology and Drug Safety
Supplement: The U.S. Food and Drug Administration's Mini-Sentinel Program
Volume 21, Issue Supplement S1, pages 282–290, January 2012
Additional Information
How to Cite
Fireman, B., Toh, S., Butler, M. G., Go, A. S., Joffe, H. V., Graham, D. J., Nelson, J. C., Daniel, G. W. and Selby, J. V. (2012), A protocol for active surveillance of acute myocardial infarction in association with the use of a new antidiabetic pharmaceutical agent. Pharmacoepidem. Drug Safe., 21: 282–290. doi: 10.1002/pds.2337
Publication History
- Issue published online: 19 JAN 2012
- Article first published online: 19 JAN 2012
Funded by
- FDA through the Department of Health and Human Services. Grant Number: HHSF223200910006I
REFERENCES
- 1U.S. Food and Drug Administration. COX-2 Selective (includes Bextra, Celebrex, and Vioxx) and Non-Selective Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm103420.htm [14 September 2011].
- 2U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA Recommends Against the Continued Use of Meridia (sibutramine). http://www.fda.gov/Drugs/DrugSafety/ucm228746.htm [14 September 2011].
- 3U.S. Food and Drug Administration. FDA significantly restricts access to the diabetes drug Avandia. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm226956.htm [14 September 2011].
- 4Center for Drug Evaluation and Research (CDER) U.S. Food and Drug Administration. Guidance for Industry: Diabetes Mellitus — Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes. U.S. Department of Health and Human Services. Bethesda, MD. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM071627.pdf [30 January 2011].
- 5, , , et al. A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes. Postgrad Med 2010; 122(3): 16–27.
- 6Does saxagliption reduce the risk of cardiovascular events when used alone or added to other diabetes medications (SAVOR-TIMI 53). http://clinicaltrials.gov/ct2/show/NCT01107886 [14 September 2011].
- 7, , . Report to FDA on a protocol for active surveillance of acute myocardial infarction in association with use of a pharmaceutical agent. http://www.mini-sentinel.org/work_products/Evaluations/AMI_Surveillance_Protocol_and_Appendices_ABC.pdf [14 September 2011].
- 8, , , et al. Developing the Sentinel System - A National Resource for Evidence Development. N Engl J Med 2011; 364: 498–499.
- 9. A basic study design for expedited safety signal evaluation based on electronic healthcare data. Pharmacoepidemiol Drug Saf 2010; 19: 858–868.
- 10. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 2003; 158: 915–920.
- 11, , , et al. Design and use of the Mini-Sentinel distributed database. Pharmacoepidemiol Drug Saf 2012; 21(S1): 23–31.
- 12, , , et al. Design for validation of acute myocardial infarction cases in Mini-Sentinel. Pharmacoepidemiol Drug Saf 2012; 21(S1): 274–281.
- 13, , , et al. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA 2010; 304: 411–418.
- 14, , , et al. Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records. Am Heart J 2004; 148(1): 99–104.
- 15, . The central role of the propensity score in observational studies for causal effects. Biometrika 1983; 70(1): 41–55.
- 16, . Invited commentary: propensity scores. Am J Epidemiol 1999; 150(4): 327–333.
- 17, , . Indications for propensity scores and review of their use in pharmacoepidemiology. Basic Clin Pharmacol Toxicol 2006; 98: 253–259.
- 18, , , , , . COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 2002; 360: 1071–1073.
- 19, . Use of disease risk scores in pharmacoepidemiologic studies. Stat Methods Med Res 2009; 18: 67–80.
- 20, , , et al. Confounder summary scores when comparing the effects of multiple drug exposures. Pharmacoepidemiol Drug Saf 2010; 19: 2–9.
- 21, , . Multivariate-adjusted pharmacoepidemiologic analyses of confidential information pooled from multiple health care utilization databases. Pharmacoepidemiol Drug Saf 2010; 19: 848–857.
- 22. Reducing Bias in a Propensity Score Matched-Pair Sample Using Greedy Matching Techniques. Sas Users Group International Conference, Vol 214–26. SAS Institute Inc.: Long Beach, CA, 2001.
- 23, , , et al. Influenza vaccination and mortality: differentiating vaccine effects from bias. Am J Epidemiol 2009; 170: 650–656.
- 24, . Interim analysis: the alpha spending function approach. Stat Med 1994; 13: 1341–1352; discussion 1353–1346.
- 25, . A conditional maximized sequential probability ratio test for pharmacovigilance. Stat Med 2010; 29: 284–295.
- 26, , , et al. A maximized sequential probability ratio test for drug and vaccine safety surveillance. Seq Anal 2011; 30: 58–78
- 27. Group sequential methods in the design and analysis of clinical trials. Biometrika 1977; 64: 191–199.
- 28, . A Multiple Testing Procedure for Clinical Trials. Biometrics 1979; 35: 549–556.
- 29, , , . Treatment effects in the presence of unmeasured confounding: dealing with observations in the tails of the propensity score distribution--a simulation study. Am J Epidemiol 2010; 172: 843–854.